Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gazyva

- PMLiVE

NHS England says yes to Roche’s Hemlibra

But stalls on funding for Actelion's Uptravi

- PMLiVE

Roche reshuffles its executive committee, again

Sophie Kornowski-Bonnet joins Reed and heads for the exit

Roche Basel Switzerland

Roche agrees $2.4bn takeover of genomics player Foundation

Offers a 29% premium on the Foundation’s recent share price

- PMLiVE

AbbVie, Roche get FDA OK for broader use of Venclexta

The drug is tipped to become a $2.5bn product by 2024

- PMLiVE

Daily Brief: Italy in turmoil, Pharma attacks Europe’s generics move and more

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

Safety scuppers combo trials with J&J/Genmab’s Darzalex

Studies revealed a “numerical increase” in patient deaths when Darzalex was combined with Roche’s Tecentriq

- PMLiVE

AbbVie trial backs chemo-free Imbruvica combo regimen

Imbruvica paired with Roche’s Gazyva for previously untreated CLL patients

- PMLiVE

Roche’s Hemlibra first drug to top standard therapy in haemophilia A

Latest data could unlock a new patient population for the Swiss pharma giant’s injection

- PMLiVE

Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

A rapid round-up of pharma, biotech and healthcare news

Roche Basel Switzerland

Another IO knockback as Tecentriq combo fails phase III trial

The bulk of CRC patients with MSS currently look set to be excluded from cancer immunotherapy

Roche Basel Switzerland

Roche eyes September FDA verdict for triple NSCLC therapy

Roche hot on the heels of Merck in first-line non-small cell lung cancer market

- PMLiVE

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more

A rapid round up of pharma, biotech and healthcare news

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links